Bullous pemphigoid is a potentially debilitating autoimmune bullous disease presenting with urticarial plaques, subepidermal bullae, erosions, and pruritus, classically in elderly individuals. This ...

A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

Findings showed 20% of patients treated with dupilumab experienced sustained disease remission at week 36 compared with 4% of those who received placebo. Treatment with dupilumab led to significant ...

Please provide your email address to receive an email when new articles are posted on . Nomacopan was well tolerated and beneficial in patients with bullous pemphigoid, according to phase 2a clinical ...

Bullous pemphigoid (BP) is a condition that affects the skin with an autoimmune etiology. It is often seen in those over the age of 80 and the prevalence is even higher in elderly people with ...

Please provide your email address to receive an email when new articles are posted on . Dupixent previously received priority review and orphan drug designation from the FDA for bullous pemphigoid.

Among people with type 2 diabetes, new treatment with a dipeptidyl peptidase 4 (DPP-4) inhibitor was linked with higher risk of a rare blistering skin condition, researchers reported. Compared with ...

Second R&D partnership with leading academic scientists for the development of CAR-Tregs TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cellular ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I have had an autoimmune disease called bullous pemphigoid ...

bullous pemphigoid leg The relationship between bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Regardless of the diagnosis of type 2 diabetes, patients with bullous ...

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a condition that predominantly affects ...

Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Bullous Pemphigoid Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and Forecast, 2025-2035" report has been added to ...